

## Genomic data<sup>1</sup> at Data Release 7: Incident Breast and Ovarian cancer; Sister Study 4% random subcohort

	<u>Total</u>	<u>DNA extracted</u> <sup>2</sup>		<u>GWAS</u> <sup>1</sup>		<u>Methylation</u> <sup>1</sup>		<u>Methylation</u> <sup>1</sup>		<u>Methylation</u> <sup>1</sup>	
	N	N	%	Oncoarray		LINE 1		27K		450K	
				N	%	N	%	N	%	N	%
<b>Sister Study participants</b>	50,884	13,432	26.4	4,912	9.7	1,035	2.0	1,043	2.0	3,073	6.0
Incident BrCa (any type) <sup>3</sup>	3,512	3,024	86.1	2,356	67.1	375	10.7	389	11.1	1,647	46.9
Incident BrCa (DCIS/Invasive) <sup>4</sup>	3,399	2,943	86.6	2,284	67.2	360	10.6	378	11.1	1,647	48.5
Incident OvCa <sup>5</sup>	237	198	83.5	149	62.9	8	3.4	7	3.0	20	8.4
<b>Random subcohort (4% of Sister Study)<sup>6</sup></b>	2,036	1,969	96.7	2,021	99.3	312	15.3	311	15.3	1,336	65.6
No BrCa (any type) and no OvCa <sup>7</sup>	1,879	1,816	96.6	1,865	99.3	273	14.5	274	14.6	1,226	65.2
Incident BrCa (any type) <sup>8</sup>	149	145	97.3	148	99.3	38	25.5	37	24.8	105	70.5
No <b>DCIS/Invasive</b> BrCa and no OvCa <sup>8</sup>	1,886	1,823	96.7	1,872	99.3	275	14.6	276	14.6	1,227	65.1
Incident <b>DCIS/Invasive</b> BrCa <sup>8</sup>	142	138	97.2	141	99.3	36	25.4	35	24.6	104	73.2
Incident OvCa <sup>8</sup>	8	8	100.0	8	100.0	1	12.5	0	--	5	62.5
<b>Other</b> <sup>9</sup>	1,137	1,079	94.9	558	49.1	382	33.6	376	33.1	192	16.9

<sup>1</sup>Table reflects N of samples sent for assay, not N of samples with usable results. Investigator cutoffs will affect N of usable samples. For study planning, more detailed information is available on request.

<sup>2</sup>DNA extracted as of 08/12/2019. >=5 µg of DNA.

<sup>3</sup>Includes 1st LCIS/DCIS/Invasive BrCa. Excludes prevalent BrCa; BrCa with unknown timing (incident vs. prevalent); and uncertain BrCa dx (BrCa possible but unlikely)

<sup>4</sup>Includes 1st DCIS/Invasive BrCa. Excludes LCIS, prevalent DCIS/Invasive BrCa and all DCIS/Invasive BrCa with unknown timing (incident vs. prevalent) or uncertain dx (BrCa possible but unlikely)

<sup>5</sup>Excludes prevalent OvCa; OvCa timing unknown; and OvCa uncertain

<sup>6</sup>Included in second sample collection (SCL)

<sup>7</sup>Excludes incident, prevalent, timing unknown and diagnosis uncertain for both BrCa and OvCa

<sup>8</sup>Includes n=0 with both incident BrCa and incident OvCa. Excludes prevalent, timing unknown and diagnosis uncertain cases

<sup>9</sup>DNA extracted for other projects (not in 4% subcohort, neither an incident BrCa or OvCa case as of Data Release 5)